| 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2009 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 303,4 M € | -51.8% | 628,9 M € | +24.9% | 503,4 M € | -9.9% | 558,8 M € | -38.1% | 902,8 M € | +312.3% | 219,0 M € | +66.5% | 131,5 M € | -18.8% | 162,0 M € | +170.5% | 59,9 M € | -5.0% | 63,0 M € | +30.4% | 48,3 M € | +5.1% | 46,0 M € | -11.5% | 51,9 M € | |
| EBITDA | 89,9 M € | -79.3% | 433,7 M € | +108.7% | 207,8 M € | -42.1% | 358,9 M € | -55.0% | 797,2 M € | +385.2% | 164,3 M € | +47.1% | 111,7 M € | -26.2% | 151,4 M € | +361.4% | 32,8 M € | -36.9% | 51,9 M € | +1.7% | 51,1 M € | +12.3% | 45,5 M € | +839.3% | -6,2 M € | |
| Operating profit | -207,7 M € | -401.1% | 69,0 M € | +136.0% | -191,7 M € | -75.9% | -108,9 M € | -127.7% | 393,9 M € | +378.5% | -141,4 M € | -1.2% | -139,8 M € | -167.9% | -52,2 M € | -4.8% | -49,8 M € | -100.0% | -24,9 M € | -58.2% | -15,7 M € | -133041.4% | -11,8 k € | +99.8% | -7,5 M € | |
| Profit/loss | 47,8 M € | -82.4% | 271,3 M € | +392.5% | -92,7 M € | +52.7% | -196,0 M € | -151.7% | 379,0 M € | +427.6% | -115,7 M € | +30.3% | -165,9 M € | -266.8% | -45,2 M € | +28.2% | -63,0 M € | -201.7% | 62,0 M € | +477.2% | -16,4 M € | +39.7% | -27,2 M € | -267.8% | -7,4 M € | |
| Equity | 2,8 Md € | +1.7% | 2,8 Md € | +5.4% | 2,6 Md € | -3.3% | 2,7 Md € | -5.8% | 2,9 Md € | +147.0% | 1,2 Md € | +19.1% | 985,0 M € | +25.8% | 783,3 M € | +80.2% | 434,8 M € | +109.7% | 207,3 M € | +47.2% | 140,8 M € | +42.8% | 98,6 M € | -9.0% | 108,4 M € | |
| Total assets | 4,0 Md € | -6.0% | 4,3 Md € | -16.0% | 5,1 Md € | -8.6% | 5,6 Md € | -6.7% | 6,0 Md € | +321.0% | 1,4 Md € | +10.8% | 1,3 Md € | +12.9% | 1,1 Md € | +100.5% | 568,5 M € | +46.5% | 388,0 M € | +6.0% | 366,1 M € | +23.5% | 296,5 M € | +109.1% | 141,8 M € | |
| Cash | 60,1 M € | -13.3% | 69,4 M € | -94.2% | 1,2 Md € | +0.3% | 1,2 Md € | +35.4% | 886,8 M € | +72.9% | 512,8 M € | +19.7% | 428,3 M € | -18.7% | 526,7 M € | +55.2% | 339,4 M € | +137.3% | 143,0 M € | +15.5% | 123,8 M € | +73.6% | 71,3 M € | +125.7% | 31,6 M € | |
| Debts | 138,7 M € | -31.3% | 201,9 M € | -16.6% | 242,1 M € | +5.0% | 230,6 M € | -5.0% | 242,7 M € | +68.1% | 144,4 M € | +41.9% | 101,7 M € | +29.7% | 78,4 M € | +27.8% | 61,4 M € | +8.9% | 56,4 M € | +4.5% | 53,9 M € | +9.6% | 49,2 M € | +116.4% | 22,7 M € | |
| Staff | 291,5 | 368,6 | 486,5 | 436,3 | 308,4 | 236,2 | 176,9 | 134,4 | 123,8 | 130,3 | 113,1 | 108,2 | 99,2 | |||||||||||||
Public limited company · Mechelen · incorporated on 06/07/1999 · 291,5 ETP
Public limited company profitable and well capitalised. Cash position declining (-13.3%).
Solid counterparty for a standard engagement.
Lakefront Biotherapeutics is a Public limited company incorporated in 1999. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Mechelen. It employs on average 291,5 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette